Efgartigimod Alfa
Efgartigimod Alfa
Definition
A human immunoglobulin G1 (IgG1)-derived Fc fragment that targets the neonatal Fc receptor (FcRn), with potential FcRn blocking activity. Upon administration, efgartigimod alfa targets, binds to and blocks FcRn, thereby preventing FcRn from recycling IgG back into the systemic circulation. This causes a reduction in IgG blood levels, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. FcRn binds to IgGs and prevents their lysosomal degradation, thereby extending IgG half-life and increases the availability of pathogenic IgG antibodies that are present in certain severe autoimmune diseases.
Also known as ARGX 113, ARGX-113, ARGX113, EFGARTIGIMOD ALFA, Efgartigimod Alfa-fcab, Vyvgart — per NCIT
Also identified as
- ATC L04AA58 per RXNORM
- ATC L04AL01 per RXNORM
- NCIT NCIT:C171817 per NCIT
- SCTID 41621711000001108 per RXNORM
- UNII 961YV2O515 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Myasthenia gravis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Musculature | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Peripheral nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.